Oncotelic Presenting Data for OT101 Against Diffuse Intrinsic Pontine Glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
September 14, 2022 08:15 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
ONCOTELIC ACQUIRES FAST TO MARKET LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.
October 04, 2021 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), executed an exclusive licensing agreement on September 30, 2021,...
ONCOTELIC TO ACQUIRE LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.
September 01, 2021 12:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), executed a binding term sheet with Autotelic Inc. to license AL-101...
Zylö Receives $1,700,000 NIH Phase II Grant to Advance Erectile Dysfunction Program into Human Trials
July 20, 2021 09:00 ET
|
Zylö Therapeutics
Funds to be used for scale-up, implementation of cGMP quality system, and pre-IND FDA meeting GREENVILLE, SC, July 20, 2021 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the...
US Erectile Dysfunction Market and Competitive Landscape Report 2021: Epidemiology, Key Products Marketed, Market Valuations and Forecast, Drugs Sales and Market Shares
June 08, 2021 04:58 ET
|
Research and Markets
Dublin, June 08, 2021 (GLOBE NEWSWIRE) -- The "US Erectile Dysfunction Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering. US Erectile Dysfunction...
Leonhardt Ventures LLC Announces Plans To Take Bids for MyoStim ED ErectiStim TM Erectile Dysfunction IP and Assets
June 02, 2021 11:32 ET
|
Leonhardt Ventures LLC
United States, California, Newport Beach, June 02, 2021 (GLOBE NEWSWIRE) -- -- Leonhardt Ventures LLC and it's innovation accelerator subsidiary Leonhardt's Launchpads by Cal-X Stars...
CURE Pharmaceutical [OTCQB:CURR] Secures Chinese Patent on its Oral Thin Films to Treat Erectile Dysfunction
March 17, 2020 08:30 ET
|
Cure Pharmaceutical Holding Corp.
OXNARD, Calif., March 17, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the allowance of Chinese Patent No....
CURE Pharmaceutical Announces Completion of FDA Pre-IND Review and Clinical Trial Plans for CUREfilm Blue™ for Erectile Dysfunction
March 26, 2019 07:25 ET
|
Cure Pharmaceutical Holding Corp.
OXNARD, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has successfully completed a pre-IND...
View Systems (VSYM) Reports Medical Therapeutics Has Profitable Quarter
June 14, 2018 08:30 ET
|
View Systems, Inc.
Baltimore, MD. , June 14, 2018 (GLOBE NEWSWIRE) -- View Systems (OTC: VSYM)., Medical Therapeutics, a concierge medical service providing aging and sexual health therapies has reported a profitable...
CURE Pharmaceutical Enters Partnership to Distribute New Erectile Dysfuntion Drug Using Company’s Proprietary CureFilm™ Into Asian Market
August 10, 2017 09:00 ET
|
CURE Pharmaceutical
OXNARD, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development...